Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I booster vaccination study of KD-414 after prior COVID-19 vaccination
jRCT2031210503Phase 1Active, not recruiting
- Sponsor
- KM Biologics
- Start
- Dec 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of KD-414 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by KM Biologics. Primary endpoints: Percentage of subjects with any adverse event, Frequency of each adverse event item and 4 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
KD-414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210503.